Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Renal Denervation Devices Market – Easy Administration of Medications
Renal denervation devices play a major role in modern healthcare and are used in treatment of uncontrolled or persistent hypertension, where hypertensive medication is ineffective. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes.
The global renal denervation devices market size was valued at US$ 88.6 million in 2017, and is expected to exhibit a CAGR of 35.5% over the forecast period (2018 – 2026).
Figure 1. Global Renal Denervation Devices Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of hypertension is expected to propel growth of the renal denervation devices market
Increasing prevalence of cardiovascular diseases (CVDs) and hypertension is expected to drive demand for renal denervation devices worldwide. For instance, according to the World Health Organization (WHO), the prevalence of hypertension in adults aged 25 and above was around 40% in 2008 worldwide. According to the American College of Cardiology (ACC)/the American Heart Association (AHA), the clinical practice guidelines of hypertension have modified the definition of hypertension, which has increased the prevalence of hypertension to 45.6% or around 103.3 million people in U.S. in 2017.
Furthermore, according to WHO 2017, Africa accounts for the highest number of high blood pressure cases worldwide, affecting around 46% of adults, owing to increasing urbanization and unhealthy lifestyles. According to the Blood Pressure Association in the U.K., the highest number of people suffering from high blood pressure was recorded in South Asia and parts of Africa, where over 50% of those with high blood pressure lived in Asia Pacific, including 226 million people in China and 199 million in India in 2015. Therefore, increasing number of high blood pressure cases is expected to boost the market growth.
However, adoption of pharmaceutical therapy for the management of hypertension is expected to limit adoption of renal denervation devices, thereby hindering the market growth. For instance, according to American College of Cardiology (ACC)/American Heart Association (AHA), the number of people adopting pharmaceutical therapy increased by 13.9 million (from 24.0 in 2013 % to 54.4% of the treated patients) in the U.S. in 2017. Moreover, around 30 million people in China choose pharmaceutical treatment for hypertension in 2017.
Figure 2. Global Renal Denervation Device Market Share (%), by Products, 2018 and 2026
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities and regulatory approvals in Europe is expected to bolster the market growth
Europe holds dominant position in the global renal denervation device market, owing to increasing research and development activities and regulatory approvals. For instance, in February 2014, Cordis Corporation, a division of Johnson & Johnson, received CE Mark for Renlane renal denervation system. The system consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.
Moreover, increasing number of clinical trials on renal denervation devices is also expected to boost the market growth. For instance, multi-center, international, single-blind, randomized, sham-controlled clinical trials of RADIANCE-HTN SOLO were conducted at 21 centers in the U.S. and 18 in Europe. The trials meet primary efficacy endpoint, according to an announcement by ReCor Medical in May 2018.
Key Players
Major players operating in the global renal denervation device market include, St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.
US :
INDIA :
UK :
JAPAN :
U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Sales Office (U.S.) : 
